The project will validate a novel lead compound against solid tumors based on copper (II) nitroprusside, a nitric oxide donor containing dual Fenton initiator metals (Cu and Fe) able to generate reactive oxygen (ROS) and peroxynitrite (ONOO-) species at tumoral sites, exhibiting a potent cytotoxicity against various types of tumor cells. This novel lead compound, patented by prof. Rizzolio’s group, was specifically designed to overcome the two main issues of ChemoDynamic Therapy (CDT): the small amount of endogenous hydrogen peroxide, and the smaller number of cations produced from the catalyst to initiate Fenton like reactions. CDT uses the tumor microenvironment to activate Fenton/Fenton-like reactions to generate strong oxidative hydroxyl radicals for tumor treatment. The advantages of the proposed approach are the following: high selectivity, no limitation in tissue penetration and negligible damage to normal tissues. Main goal of the project is to evaluate the efficacy and toxicity of the pharmaceutical formulations exploiting an organ-on-chip model of the ovarian cancer microenvironment, and to cross-validate the in vitro results with those obtained in the animal model (by CRO-Aviano).